These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 15150206)

  • 21. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs.
    Briesacher B; Kamal-Bahl S; Hochberg M; Orwig D; Kahler KH
    Arch Intern Med; 2004 Aug 9-23; 164(15):1679-84. PubMed ID: 15302639
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Problems due to medication costs among VA and non-VA patients with chronic illnesses.
    Piette JD; Heisler M
    Am J Manag Care; 2004 Nov; 10(11 Pt 2):861-8. PubMed ID: 15609740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of medication adherence on hospitalization risk and healthcare cost.
    Sokol MC; McGuigan KA; Verbrugge RR; Epstein RS
    Med Care; 2005 Jun; 43(6):521-30. PubMed ID: 15908846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approaches to pharmacy benefit management and the impact of consumer cost sharing.
    Olson BM
    Clin Ther; 2003 Jan; 25(1):250-72. PubMed ID: 12637125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic conditions and disabilities: trends and issues for private drug plans.
    Boccuti C; Moon M; Dowling K
    Policy Brief Commonw Fund; 2003 Oct; (680):1-10. PubMed ID: 14562797
    [No Abstract]   [Full Text] [Related]  

  • 26. Assessing the effect of Taiwan's outpatient prescription drug copayment policy in the elderly.
    Liu SZ; Romeis JC
    Med Care; 2003 Dec; 41(12):1331-42. PubMed ID: 14668666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limited options to manage specialty drug spending.
    Tu HT; Samuel DR
    Res Brief; 2012 Apr; (22):1-13. PubMed ID: 23155549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacy discount card programs: catching up with the health markets.
    Edwards D
    Empl Benefits J; 2002 Sep; 27(3):42-3. PubMed ID: 12219563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effects of expanded mental health benefits on treatment costs.
    Sasso AT; Lurie IZ; Lee JU; Lindrooth RC
    J Ment Health Policy Econ; 2006 Mar; 9(1):25-33. PubMed ID: 16733269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of Specialty Medication Use for Common Chronic Inflammatory Diseases Among Health Exchange and Other Commercially Insured Members.
    Chen X; Gautam S; Ruggieri A; Richards T; Devries A; Sylwestrzak G
    J Manag Care Spec Pharm; 2018 Jan; 24(1):12-19. PubMed ID: 29290173
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
    Hynd A; Roughead EE; Preen DB; Glover J; Bulsara M; Semmens J
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1091-9. PubMed ID: 18942671
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in prescription drug expenditures by Medicaid enrollees.
    Banthin JS; Miller GE
    Med Care; 2006 May; 44(5 Suppl):I27-35. PubMed ID: 16625061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controlling prescription drug expenditures: a report of success.
    Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
    Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Can linking co-payment for drugs to evidence on treatment value improve health outcomes and contain healthcare costs?].
    Triki N; Pliskin JS; Greenberg D
    Harefuah; 2010 Aug; 149(8):524-8, 550. PubMed ID: 21341433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prescription drug co-payments and cost-related medication underuse.
    Wagner TH; Heisler M; Piette JD
    Health Econ Policy Law; 2008 Jan; 3(Pt 1):51-67. PubMed ID: 18634632
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specialty pharmacy management adjusts to new financial realities.
    Reinke T
    Manag Care; 2013 Apr; 22(4):13-4. PubMed ID: 23678558
    [No Abstract]   [Full Text] [Related]  

  • 39. The effects of copayments and generic substitution on the use and costs of prescription drugs.
    Smith DG
    Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing the intricate Web of prescription drugs.
    Eber BL
    Benefits Q; 2003; 19(1):45-50. PubMed ID: 12608118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.